Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AAM CEO Urges President-Elect Biden To Act On Access

As Dan Leonard Lays Out 2021 Outlook For US Generics And Biosimilars

Executive Summary

Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.

You may also be interested in...



AAM Urges Supreme Court To Uphold Inter Partes Review

The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.

AAM Welcomes US Access Bill

The AAM has backed the draft Protecting Access to Affordable Medicines Act of 2020 introduced by the US House of Representatives members GK Butterfield, Billy Long and Tony Cardenas and has urged House members to co-sponsor the bill, which aims to protect low-cost generic medicines from a “misguided” Medicaid penalty.

US Saves $313bn From Generics And $2.2bn From Biosimilars

The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.

Related Content

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel